{"id":819458,"date":"2025-02-27T16:10:12","date_gmt":"2025-02-27T21:10:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-reports-record-fourth-quarter-and-full-year-2024-financial-results\/"},"modified":"2025-02-27T16:10:12","modified_gmt":"2025-02-27T21:10:12","slug":"collegium-reports-record-fourth-quarter-and-full-year-2024-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-reports-record-fourth-quarter-and-full-year-2024-financial-results\/","title":{"rendered":"Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results"},"content":{"rendered":"
\n

\n \u2013 Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million \u2013<\/em>\n <\/p>\n

\n \u2013 Reported Quarterly Jornay PM<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7\u00a0<\/em>
\n Million \u2013 <\/em>\n <\/p>\n

\n \u2013 Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million <\/em>\u2013<\/p>\n

\n \u2013 Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million <\/em>\u2013<\/p>\n

\n \u2013 Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; <\/em>
\n
\n Repurchased $60.0 Million in Shares in 2024 \u2013<\/em>\n <\/p>\n

\n \u2013 Reaffirmed Full-Year 2025 Guidance<\/em>
\n \u2013<\/em>\n <\/p>\n

\n \u2013 Conference Call Scheduled for Today at 4:30 p.m. ET \u2013<\/em>\n <\/p>\n

STOUGHTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.<\/a> (Nasdaq: COLL) today reported its financial results for the quarter and full year ended December 31, 2024, and provided a business update.<\/p>\n

\u201c2024 was a year of strong execution for Collegium, marked by robust performance in our pain portfolio and the addition of Jornay PM, establishing our presence in neuropsychiatry and reaffirming our commitment to helping improve the lives of people living with serious medical conditions. This was made possible thanks to the dedication of our talented team,\u201d said Vikram Karnani, President and Chief Executive Officer. \u201cWe drove record financial results in 2024 and are poised for a new phase of growth in 2025 and beyond. We are focused on growing Jornay PM, maximizing our pain portfolio, and strategically deploying capital to create value and continue to build a leading, diversified biopharmaceutical company.\u201d<\/p>\n

\u201cWe are proud to have delivered on our financial commitments and strategic priorities for 2024, including growing total revenue by 11% and adjusted EBITDA by 9%, generating robust operating cash flows in a year that we completed an acquisition, and deploying capital to expand and diversify our business while executing $60 million in share repurchases,\u201d said Colleen Tupper, Chief Financial Officer. \u201cWe are in a position of financial strength, ending the year with net debt to adjusted EBITDA of less than two times. We are committed to creating long-term value for our shareholders by executing on our commercial priorities and strategically deploying capital in a disciplined manner.\u201d<\/p>\n

\n Business Highlights<\/strong>\n <\/p>\n